32,647 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Brophy Wealth Management LLC

Brophy Wealth Management LLC bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 32,647 shares of the biopharmaceutical company's stock, valued at approximately $945,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. M&G Plc grew its stake in Pfizer by 14.5% during the 2nd quarter. M&G Plc now owns 813,423 shares of the biopharmaceutical company's stock worth $22,776,000 after buying an additional 103,254 shares during the last quarter. Maia Wealth LLC acquired a new position in shares of Pfizer during the second quarter worth approximately $372,000. Wealth Enhancement Advisory Services LLC increased its stake in Pfizer by 1.4% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 1,648,811 shares of the biopharmaceutical company's stock valued at $46,134,000 after buying an additional 21,970 shares during the period. Great Valley Advisor Group Inc. raised its holdings in shares of Pfizer by 6.1% in the 2nd quarter. Great Valley Advisor Group Inc. now owns 192,028 shares of the biopharmaceutical company's stock worth $5,373,000 after purchasing an additional 10,993 shares in the last quarter. Finally, ORG Partners LLC increased its holdings in shares of Pfizer by 1,729.9% in the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company's stock valued at $1,327,000 after buying an additional 44,458 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PFE. Citigroup began coverage on Pfizer in a report on Friday, October 25th. They issued a "neutral" rating and a $30.00 target price on the stock. Sanford C. Bernstein started coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price objective for the company. Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They set an "underperform" rating and a $25.00 price target for the company. StockNews.com downgraded Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Finally, Bank of America reissued a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $32.64.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the business's stock in a transaction on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company's stock, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.06% of the company's stock.

Pfizer Price Performance

Pfizer stock traded down $0.50 during midday trading on Tuesday, reaching $25.60. The company's stock had a trading volume of 24,758,965 shares, compared to its average volume of 38,445,723. The stock has a market cap of $145.07 billion, a PE ratio of 34.91, a price-to-earnings-growth ratio of 0.70 and a beta of 0.65. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business has a 50-day moving average price of $27.42 and a 200-day moving average price of $28.36. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analysts' expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business's quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.17) earnings per share. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 8th were issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.56%. The ex-dividend date of this dividend was Friday, November 8th. Pfizer's payout ratio is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.